T. Rowe Price Investment Management, Inc.

Position in NKTX — Nkarta, Inc.

CIK 1897612 BALTIMORE, MD

Position in NKTX

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$1,287,743

-$2,295,753 QoQ

Shares Held

455,033

-42.6% QoQ

Ownership

0.635%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#26

of 136 holders

Holding Since

Sep 2022

10 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

T. Rowe Price Investment Management, Inc. holds $12,244,164,567 across 51 Biotechnology names. NKTX ranks #49 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	6,754,846	$1,801,652,525
2	ALNY	Alnylam Pharmaceuticals, Inc.	5,642,173	$1,698,463,338
3	CYTK	Cytokinetics Inc	18,718,498	$1,594,628,844
4	KYMR	Kymera Therapeutics, Inc.	6,257,261	$717,520,118
5	PCVX	Vaxcyte, Inc.	12,207,450	$709,619,068
6	DYN	Dyne Therapeutics, Inc.	30,912,287	$686,561,894
7	CGON	CG Oncology, Inc.	6,616,899	$470,130,673
8	IMNM	Immunome Inc.	19,676,883	$416,953,150

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,287,743	455,033	-42.6%	Shares	Sole	2026-08-14
2024-09-30	$3,583,496	792,809	-1.9%	Shares	Sole	2024-11-14
2024-06-30	$4,778,625	808,566	-40.3%	Shares	Sole	2024-08-14
2024-03-31	$14,651,020	1,355,321	+192.8%	Shares	Sole	2024-05-15
2023-12-31	$3,054,730	462,838	-89.7%	Shares	Sole	2024-02-14
2023-09-30	$6,257,064	4,501,485	-9.4%	Shares	Sole	2023-11-14
2023-06-30	$10,886,522	4,971,015	-4.0%	Shares	Sole	2023-08-14
2023-03-31	$18,381,147	5,177,788	+9.0%	Shares	Sole	2023-05-15
2022-12-31	$28,447,114	4,749,101	+18.6%	Shares	Sole	2023-02-14
2022-09-30	$52,684,007	4,003,344	—	Shares	Sole	2022-11-14
No filing history on record for this holder in this stock.